insights_auto
Why is GIS up 3,18%?
Dive Deeperchevron_right
GIS:ETR
Gilead Sciences, Inc
€133,64
arrow_upward
+3,18%(+4,12) 1D
9 ຕ.ລ., 17 ໂມງ 35 ນາທີ 39 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GIS...
Open
€131,64
High
€133,64
Low
€130,76
Mkt. cap
187,44 ຕື້
Avg. vol.
683,00
Volume
3,01 ພັນ
52-wk high
€136,24
52-wk low
€98,96
No. of employees
17 ພັນ
Open
€131,64
High
€133,64
Low
€130,76
Mkt. cap
187,44 ຕື້
Avg. vol.
683,00
Volume
3,01 ພັນ
52-wk high
€136,24
52-wk low
€98,96
No. of employees
17 ພັນ
News stories
From web sources and news partners
Simply Wall Street
·
1 ຊົ່ວໂມງກ່ອນ
Gilead Sciences (GILD) Could Be Trading At A 18% Premium Following Strong Earnings
AD HOC NEWS
·
3 ຊົ່ວໂມງກ່ອນ
Gilead Sciences stock trades 0.17 percent above its Xetra close of EUR 134.84
Trefis
·
10 ຊົ່ວໂມງກ່ອນ
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?
AD HOC NEWS
·
21 ຊົ່ວໂມງກ່ອນ
RBC raises target for Gilead Sciences stock to USD 126.00
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 ພັນ
Founded22 ມິ.ຖ. 1987
HeadquartersFoster City, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websitegilead.com